Thyroid hormone treatment of acute cardiovascular compromise

• US 5,158,978 A
• Filed: 06/18/1991
• Issued: 10/27/1992
• Est. Priority Date: 02/05/1990
• Status: Expired due to Term

• Current Assignee: BTG International Inc. (Boston Scientific Corporation)
• Original Assignee: British Technology Group Ltd. (Boston Scientific Corporation)
• Inventors: Rubin, Leo
• Primary Examiner(s): Raymond, Richard L.
• Assistant Examiner(s): Hollinden, Gary E.
• Application Number:
  US07/723,716
• Time in Patent Office: 497 Days
• Field of Search: 514/567, 514/821, 514/921
• US Class Current: 514/567
• CPC Class Codes: A61K 31/195 having an amino group

Abstract

A method for the treatment of patients with acute cardiovascular compromise by administering a therapeutically effective amount of thyroid hormones. Methods of administration are included.

Claims

1. A method for emergency treatment of a patient with spontaneous cardiac arrest for restoring effective cardiac function, comprising administering to the patient a therapeutically effective amount of a thyroid hormone selected from the group consisting of thyroxine, triiodothyronine and agonists thereof.

2. A method according to claim 1, wherein the amount of thyroid hormone administered to the patient is effective for restoring cardiac function.

3. A method according to claim 1, wherein the thyroid hormone is administered by direct injection into a heart cavity of the patient.

4. A method according to claim 1, wherein the thyroid hormone is administered by parenteral injection.

5. A method according to claim 4, wherein the thyroid hormone is administered by parenteral intravenous injection.

6. A method according to claim 4, wherein the thyroid hormone is administered by direct parenteral injection into a central venous line of the patient.

7. A method according to claim 1, wherein the thyroid hormone is administered directly to the pulmonary system of the patient.

8. A method according to claim 7, wherein the thyroid hormone is administered directly to the pulmonary system by direct endotracheal injection.

9. A method according to claim 7, wherein the thyroid hormone is administered directly to the pulmonary system by infusion through a respiratory airway of the patient.

10. A method according to claim 1, 3, or 6, wherein the thyroid hormone is administered in at least one rapid bolus injection.

11. A method according to claim 1, wherein the thyroid hormone is thyroxine.

12. A method according to claim 11, wherein the therapeutically effective amount of thyroxine is in the range of 500 μ

g to 10 g.

13. A method according to claim 1, wherein the thyroid hormone is triiodothyronine.

14. A method according to claim 13, wherein the therapeutically effective amount of triiodothyronine is in the range of 50 μ

g to 1 mg.

15. A method for emergency treatment of a patient with spontaneous cardiac arrest resulting from electromechanical dissociation comprising administering to the patient a thyroid hormone selected from the group consisting of thyroxine, triiodothyronine and agonists thereof in an amount effective to establish cardiac function.

16. A method according to claim 15, wherein the thyroid hormone is administered by direct injection into a heart cavity of the patient.

17. A method according to claim 15, wherein the thyroid hormone is administered by parenteral injection.

18. A method according to claim 17, wherein the thyroid hormone is administered by parenteral intravenous injection.

19. A method according to claim 17, wherein the thyroid hormone is administered by direct parenteral injection into a central venous line of the patient.

20. A method according to claim 15, wherein the thyroid hormone is administered directly to the pulmonary system of the patient.

21. A method according to claim 20, wherein the thyroid hormone is administered directly to the pulmonary system by direct endotracheal injection.

22. A method according to claim 20, wherein the thyroid hormone is administered directly to the pulmonary system by infusion through a respiratory airway of the patient.

23. A method according to claim 15, 16, or 19, wherein the thyroid hormone is administered in at least one rapid bolus injection.

24. A method according to claim 15, wherein the thyroid hormone is thyroxine.

25. A method according to claim 24, wherein the therapeutically effective amount of thyroxine is in the range of 500 μ

g to 10 g.

26. A method according to claim 15, wherein the thyroid hormone is triiodothyronine.

27. A method according to claim 26, wherein the therapeutically effective amount of triiodothyronine is in the range of 50 μ

g to 1 mg.

28. A method for emergency treatment to restore effective cardiac function in a patient with spontaneous cardiac electrical standstill, comprising administering to the patient a thyroid hormone selected from the group consisting of thyroxine, triiodothyronine and agonists thereof in an amount effective to establish a cardiac rhythm.

29. A method according to claim 28, wherein the cardiac rhythm is a normal sinus rhythm.

30. A method according to claim 28, wherein the thyroid hormone is administered by direct injection into a heart cavity of the patient.

31. A method according to claim 28, wherein the thyroid hormone is administered by parenteral injection.

32. A method according to claim 31, wherein the thyroid hormone is administered by parenteral intravenous injection.

33. A method according to claim 31, wherein the thyroid hormone is administered by direct parenteral injection into a central venous line of the patient.

34. A method according to claim 28, wherein the thyroid hormone is administered directly to the pulmonary system of the patient.

35. A method according to claim 34, wherein the thyroid hormone is administered directly to the pulmonary system by direct endotracheal injection.

36. A method according to claim 34, wherein the thyroid hormone is administered directly to the pulmonary system by infusion through a respiratory airway of the patient.

37. A method according to claim 28, 30, or 33, wherein the thyroid hormone is administered in at least one rapid bolus injection.

38. A method according to claim 28, wherein the thyroid hormone is thyroxine.

39. A method according to claim 38, wherein the therapeutically effective amount of thyroxine is in the range of 500 μ

g to 10 g.

40. A method according to claim 28, wherein the thyroid hormone is triiodothyronine.

41. A method according to claim 40, wherein the therapeutically effective amount of triiodothyronine is in the range of 50 μ

g to 1 mg.

42. A method for emergency treatment to restore effective cardiac function in a patient with spontaneous cardiac electrical standstill caused by a disease, comprising administering to the patient a thyroid hormone selected from the group consisting of thyroxine, triiodothyronine and agonists thereof in an amount effective to establish a cardiac rhythm.

43. A method according to claim 42, wherein the cardiac rhythm is a normal sinus rhythm.

44. A method according to claim 42, wherein the thyroid hormone is administered by direct injection into a heart cavity of the patient.

45. A method according to claim 42, wherein the thyroid hormone is administered by parenteral injection.

46. A method according to claim 45, wherein the thyroid hormone is administered by parenteral intravenous injection.

47. A method according to claim 45, wherein the thyroid hormone is administered by direct parenteral injection into a central venous line of the patient.

48. A method according to claim 42, wherein the thyroid hormone is administered directly to the pulmonary system of the patient.

49. A method according to claim 48, wherein the thyroid hormone is administered directly to the pulmonary system by direct endotracheal injection.

50. A method according to claim 48, wherein the thyroid hormone is administered directly to the pulmonary system by infusion through a respiratory airway of the patient.

51. A method according to claim 42, 44, or 47, wherein the thyroid hormone is administered in at least one rapid bolus injection.

52. A method according to claim 42, wherein the thyroid hormone is thyroxine.

53. A method according to claim 42, wherein the therapeutically effective amount of thyroxine is in the range of 500 μ

g to 10 g.

54. A method according to claim 42, wherein the thyroid hormone is triiodothyronine.

55. A method according to claim 54, wherein the therapeutically effective amount of triiodothyronine is in the range of 50 μ

g to 1 mg.

56. A method for establishing effective cardiac function in a heart of a patient in spontaneous cardiac arrest in which defibrillation is applied and does not establish a cardiac rhythm in the patient, comprising administering to the patient a thyroid hormone selected from the group consisting of thyroxine, triiodothyronine and agonists thereof in an amount effective to establish a cardiac rhythm.

57. A method according to claim 56, wherein the cardiac rhythm is a normal sinus rhythm.

58. A method according to claim 56, wherein the thyroid hormone is administered by direct injection into a heart cavity of the patient.

59. A method according to claim 56, wherein the thyroid hormone is administered by parenteral injection.

60. A method according to claim 59, wherein the thyroid hormone is administered by parenteral intravenous injection.

61. A method according to claim 59, wherein the thyroid hormone is administered by direct parenteral injection into a central venous line of the patient.

62. A method according to claim 56, wherein the thyroid hormone is administered directly to the pulmonary system of the patient.

63. A method according to claim 62, wherein the thyroid hormone is administered directly to the pulmonary system by direct endotracheal injection.

64. A method according to claim 62, wherein the thyroid hormone is administered directly to the pulmonary system by infusion through a respiratory airway of the patient.

65. A method according to claim 56, 58, or 61, wherein the thyroid hormone is administered in at least one rapid bolus injection.

66. A method according to claim 56, wherein the thyroid hormone is thyroxine.

67. A method according to claim 66, wherein the therapeutically effective amount of thyroxine is in the range of 500 μ

g to 10 g.

68. A method according to claim 56, wherein the thyroid hormone is triiodothyronine.

69. A method according to claim 68, wherein the therapeutically effective amount of triiodothyronine is in the range of 50 μ

g to 1 mg.